Aptargroup Inc (ATR)
Fair ValueFundamental
66
Price
$120.22
Market Cap
$7.91B
Part 1 · What the company is worth
Overview
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users
It supplies the elastomeric stoppers, seals and injection delivery systems that compete head-on with Aptar Pharma's injectables business for the same drug makers.
Through Silgan Dispensing Systems it makes the same pumps, trigger sprayers and dispensing closures Aptar sells to beauty, home care and food and beverage brands.
This French maker of nasal sprays, preservative-free eyedroppers and inhalers bids for the same drug-delivery device contracts with pharmaceutical companies as Aptar Pharma.
The German group sells inhalers, pen injectors and primary pharmaceutical packaging, and also cosmetics packaging, to the same pharma and beauty customers Aptar serves in Europe and the United States.
After absorbing Berry Global in April 2025 it is a large supplier of closures, dispensing components and healthcare packaging to the consumer and pharmaceutical brands Aptar depends on.
The privately held German closure specialist competes with Aptar's Food + Beverage segment on dispensing and non-dispensing plastic caps for drinks, edible oils and household liquids.
Balance Sheet & Liquidity
Revenue
$3.93B
Trailing 12 months (through 6/30/2026)
Net Income
$363M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$300M
Total Equity
$2.67B
Total Liabilities
$2.57B
Current Ratio
1.61
Interest Coverage
7.52
Debt/EBITDA
1.79
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$154.38
Current Price
$120.22
Margin of Safety
+22.1%
Fair Value Range
$116.80 - $191.96
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
21.91
ROE
14.7%
P/B Ratio
2.93
P/FCF
24.82
Gross Margin
-
ROIC
9.4%
Profitability Radar
Value Creation (Economic Moat)
ROIC
9.4%
WACC
7.2%
ROIC − WACC
+2.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (21)
- EPS shows upward trend
- EPS CAGR 6.02%
- Price CAGR 5.45%
- ROIC 9.4%
- P/FCF 24.82
- P/B Ratio 2.93
- Debt/Equity ratio
- Operating Margin 12.1%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 13.6%
- Revenue Growth 5Y 5.2%
- Analyst Consensus 83% Buy
- Earnings Surprise avg 4.0%
- PEG Ratio 1.66
- Earnings Quality (OCF/NI) 1.61
- Share Dilution -1.5%
- Piotroski F-Score 5/9
Failed (5)
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Net Margin Trend 9.2% vs 10.8%
Unavailable (2)
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
No institutional filings reported for this company.
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Gael Touya | CEO, President & Director | 55 |
| Ms. Vanessa Kanu | Executive VP & CFO | 47 |
| Mr. Stephan B. Tanda | Director & Advisor | 60 |
| Mr. Marc Prieur | President of Aptar Beauty | 59 |
| Ms. Xiangwei Gong | Executive VP of Strategic Group Development & President of Aptar Asia | 55 |
| Mr. Hedi Tlili | President of Aptar Closures | 50 |
| Mr. Aditya J. Gandhi | VP, Principal Accounting Officer & Chief Accounting Officer | 45 |
| Ms. Mary Skafidas | Senior Vice President of Investor Relations & Communications | - |
| Ms. Irene Hudson | Executive VP, Chief Legal Officer & Corporate Secretary | 48 |
| Ms. Shiela Pallerne Vinczeller | Chief Human Resources Officer | 61 |
Audit Risk
1
Board Risk
1
Compensation Risk
2
Shareholder Rights Risk
5
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-06
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-31
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-21
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for ATR, sourced from Markets Gazette.
- 28d agoPOSITIVEATR (JV Leonardo-Airbus), maxi ordine da 1 miliardo di dollari dall'indiana FLY91
Indian regional airline FLY91 has placed a landmark order for 40 ATR 72-600 aircraft, valued at approximately $1 billion. This significant deal represents the largest order for ATR globally from a single airline. The ATR 72-600 is a turboprop regional airliner, and this order underscores FLY91's commitment to expanding its regional network. For investors in Leonardo (a partner in the ATR joint venture), this order signals strong demand for regional aircraft and a positive outlook for the turboprop market, potentially boosting future revenues and profitability.
- 2/28/2026POSITIVERiver Road Loads Up on ATR With 917,000 Shares in New Position
River Road, a prominent investment manager, has announced the establishment of a new significant position in AptarGroup Inc., acquiring 917,000 shares. AptarGroup is a global provider of proprietary dispensing and sealing solutions for the healthcare, beauty, and consumer markets. This strategic move by River Road signals strong confidence in AptarGroup's future prospects, suggesting the company may be undervalued or poised for significant growth. Investors might interpret this as a bullish signal, indicating potential increased interest and demand for ATR shares, given its robust global market positioning.
via Markets Gazette